Miracor Medical SA

Miracor Medical SA, commonly known as Miracor Medical, is a privately held medical device company headquartered in Awans, Belgium, founded in 2008. The company is venture capital-backed, having raised approximately $88.9M to $117M across multiple funding rounds, including a €24M to $28.5M Series E round in September 2020. Miracor Medical is a small company, with reported employee counts ranging from 5 to 50.

Miracor Medical specializes in developing innovative solutions for the treatment of severe cardiac diseases. Its primary product is the PiCSO® Impulse System (Pressure-controlled Intermittent Coronary Sinus Occlusion system), designed to reduce infarct size and improve cardiac function for patients suffering from acute myocardial infarction (AMI) or ST-elevated myocardial infarction (STEMI). The system operates by intermittently occluding the coronary sinus outflow during percutaneous coronary intervention (PCI), which redistributes blood to ischemic areas, clears microcirculation, and helps remove deleterious agents. The PiCSO Impulse System received CE Mark approval for commercialization in Europe in June 2020 and FDA Breakthrough Device Designation in the U.S. in 2019, but is not yet available for sale in either market as of June 2026.

Miracor Medical exhibits an active, two-way patent litigation posture. The company has appeared in a total of six tracked cases, acting as a plaintiff in two suits and a defendant in four. Its litigation activity includes cases in the U.S. District Court for the Northern District of Illinois and the Patent Trial and Appeal Board (PTAB).

All tracked patent litigation involves Abbott Laboratories as the opposing party. Miracor Medical SA has sued Abbott Laboratories in U.S. District Courts, while Abbott Laboratories, along with Unified Patents, has filed petitions against Miracor Medical SA at the PTAB. These cases, all initiated between late 2023 and early 2025, suggest a focused intellectual property dispute between the two medical device companies.